Tat-NR2B9c

a synthetic peptide consisting of the C-terminal 9 amino acids of the NR2B subunit of the NMDA receptor fused to the cell membrane protein transduction domain of the HIV-1-Tat protein

Networked: 14 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Tymianski, Michael: 3 articles (03/2016 - 11/2011)
2.	Edwards, Adam B: 2 articles (09/2022 - 10/2020)
3.	Knuckey, Neville W: 2 articles (09/2022 - 10/2020)
4.	Mastaglia, Frank L: 2 articles (09/2022 - 10/2020)
5.	Cui, Hong: 2 articles (03/2016 - 11/2011)
6.	Aarts, Michelle M: 2 articles (12/2013 - 07/2013)
7.	Cook, Douglas J: 2 articles (10/2012 - 11/2011)
8.	Meloni, Bruno: 1 article (09/2022)
9.	Yip, Kwok-Ho: 1 article (09/2022)
10.	Meloni, Bruno P: 1 article (10/2020)

Related Diseases

1.	Stroke (Strokes) 12/01/2013 - "Tat-NR2B9c significantly reduces stroke-related cortical dysfunction as evidenced by greater recovery of fEPs and EEG power; illustrating the immediate effects of the compound on poststroke brain function. " 10/03/2012 - "We show that primates treated with Tat-NR2B9c after the onset of embolic strokes exhibited significantly reduced numbers and volumes of strokes, as visualized by diffusion- and T2-weighted magnetic resonance imaging. " 01/01/2019 - "We synthesized Tat-NR2B9c loaded self-assembled activatable protein nanoparticles, termed TN-APNPs, and demonstrated that TN-APNPs enhanced the delivery of Tat-NR2B9c to the brain lesion in stroke. " 01/01/2019 - "Furthermore, UCCB01-144 was neuroprotective in a transient stroke model in rats, and in contrast to Tat-NR2B9c, high dose of UCCB01-144 did not lead to significant changes in mean arterial blood pressure or heart rate. " 03/01/2016 - "Tat-NR2B9c, a clinical-stage stroke neuroprotectant validated in rats and primates, was recently deemed ineffective in mice. "
2.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/01/2016 - "The R18 Polyarginine Peptide Is More Effective Than the TAT-NR2B9c (NA-1) Peptide When Administered 60 Minutes after Permanent Middle Cerebral Artery Occlusion in the Rat." 11/01/2011 - "Rats were subjected to permanent middle cerebral artery occlusion by the suture occlusion method and were treated 1 hour thereafter with a single 5-minute intravenous infusion of the postsynaptic density-95 protein inhibitor Tat-NR2B9c (7.5 mg/kg) or saline (n=8/group). "
3.	Ischemia 11/30/2023 - "Tat-NR2B9c (NA-1) ameliorated neurofunctional deficit, reduced cerebral infarction, mitigated blood-brain barrier injury and improved its integrity following ischemia-reperfusion, leading to less cerebral edema. " 11/30/2023 - "At the same time, Tat-NR2B9c (NA-1) downregulated neuronal nitric oxide synthase and matrix metalloprotease-9, while reversing the ischemia-induced downregulation of endothelial nitric oxide synthase in brain. " 12/01/2013 - "Tat-NR2B9c peptide, which confers neuroprotection by uncoupling the PSD-95 protein from N-methyl-D-aspartate receptor (NMDAR), was administered 5 minutes before ischemia. "
4.	Cerebral Infarction 11/30/2023 - "The therapeutic efficacy of Tat-NR2B9c was assessed in terms of the degree of neurological deficit and cerebral infarction, integrity of the blood-brain barrier, cerebral water content, as well as expression of PSD-95, nitric oxide synthase, and matrix metalloprotease-9. " 11/30/2023 - "Tat-NR2B9c (NA-1) ameliorated neurofunctional deficit, reduced cerebral infarction, mitigated blood-brain barrier injury and improved its integrity following ischemia-reperfusion, leading to less cerebral edema. "
5.	Brain Edema (Cerebral Edema) 11/30/2023 - "Tat-NR2B9c (NA-1) ameliorated neurofunctional deficit, reduced cerebral infarction, mitigated blood-brain barrier injury and improved its integrity following ischemia-reperfusion, leading to less cerebral edema. "

Related Drugs and Biologics

1.	Peptides (Polypeptides)
2.	polyarginine
3.	Nitric Oxide Synthase (NO Synthase)
4.	N-Methyl-D-Aspartate Receptors (NMDA Receptors)
5.	Neuroprotective Agents
6.	Proteins (Proteins, Gene)
7.	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)
8.	Nitric Oxide Synthase Type I (Neuronal Nitric Oxide Synthase)
9.	Protamines (Protamine Sulfate)
10.	Histamine (Histamine Dihydrochloride)

Related Therapies and Procedures

1.	Sutures (Suture)
2.	Spinal Injections
3.	Intravenous Infusions